FGL vs NSI-189
A side-by-side research comparison of FGL and NSI-189 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FGL | NSI-189 |
|---|---|---|
| Full name | FGL (NCAM-Derived Peptide) | NSI-189 Phosphate (Neurogenic Compound) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Investigational |
| Mechanism | Mimics NCAM FG loop interacting with FGFR1 to promote LTP, neurite outgrowth, neuronal survival, and presynaptic function enhancement. | Stimulates hippocampal neural stem cell proliferation and differentiation via Akt/CREB/BDNF signaling. Increases hippocampal volume visible on MRI. |
| Molecular weight | ~1,800 Da | 366.4 Da |
| Half-life | 4-8 hours | 18-22 hours |
| Bioavailability | Moderate (SubQ, partial BBB crossing) | High (oral) |
| Typical dose | 1-5 mg/kg (research) | 40-80 mg |
| Frequency | Daily or every other day | Once daily |
| Route | Subcutaneous | Oral |
FGL reported benefits
- Synaptic plasticity
- LTP facilitation
- Memory improvement
- Neurotrophic effects
- FGFR activation
NSI-189 reported benefits
- Hippocampal neurogenesis
- Measurable brain volume increase
- Cognitive enhancement
- Antidepressant effects
- Long-term neural benefit
Related comparisons
Research and educational reference only. Not medical advice.